US Flag logoAn official website of the United States government
Defining and Overcoming Intrinsic T Cell Dysfunction to Enable Pediatric Immunotherapy
dbGaP
Data Resource:  dbGaP
Point of Contact:  
Kai Tan,  
Project

About This Dataset
T-cells from 71 children and young adults with B-cell malignancies on trial to receive anti-CD19 CAR T-cell therapy were analyzed. These T-cells represent the pre-manufacture T-cells that were subsequently used for CAR T manufacture. Bulk RNA-Seq was performed on sorted T-cell subsets for all patients, in addition to CITE-Seq and single-cell ATAC-Seq on a subset of 6 patients. The primary clinical outcome was duration of B-cell aplasia, a surrogate measure of functional CAR T-cell persistence. From these data, molecular signatures associated with long and short-term CAR T-cell persistence were identified. This data submission includes bulk RNA-Seq, CITE-Seq, and single-cell ATAC-Seq data from this study.
Core Data Elements
Number of Cases
84
Case Sex
Female (42); Male (42)
Case Age At Diagnosis
0 to 4 years (17); 5 to 9 years (22); 10 to 14 years (22); 15 to 19 years (14); 20 to 24 years (7); 25 to 29 years (2)
Case Race
Not Reported (84)
Case Ethnicity
Not Reported (84)
Case Disease Diagnosis
Acute Lymphoblastic Leukemia (82); Hodgkin Lymphoma (2)
Case Tumor Site
Peripheral Blood (84)
Number of Samples
355
Sample Assay Method
RNA Sequencing (355)
Additional Data Elements
CLINICAL TRIAL IDENTIFIER
DBGAP STUDY IDENTIFIER
Grant Information
U01CA232361
Defining and overcoming intrinsic T cell dysfunction to enable pediatric immunotherapy
U2CCA233285
Center for pediatric tumor cell atlas
Charts
Female (42); Male (42)
42Female